News
PURPOSETo assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback